The European Medicines Agency (EMA) has developed a three-year plan to formalize, structure and develop interactions with the academic community.
The European Medicines Agency (EMA) has developed a three-year plan to formalize, structure and develop interactions with the academic community.
“Academia plays an important role in helping the EU medicines regulatory network keep abreast of the opportunities and challenges brought by science, be it in the context of the development, assessment or safety monitoring of medicines,” noted EMA’s Executive Director Guido Rasi in a statement. “The framework will allow us to integrate cutting-edge scientific knowledge more tightly into our activities. It will also help academic start-ups benefit from advice from the EU regulatory network to translate their discoveries into patient-focused medicines.”
The framework’s objectives are to:
The framework builds on EMA’s experience in interacting with stakeholder associations representing patients and consumers, healthcare professionals and the pharmaceutical industry, continued the statement. The agency has also published a new web page for academia providing links to content that is likely to be of interest, and a section describing the way EMA interacts with academia, with more detail on the collaboration framework and action plan and useful resources for academics.
According to Prof. Piet H. van der Graaf, of the Leiden Academic Centre for Drug Research (LACDR) in The Netherlands, “This is an important step towards a strong alignment of the European excellence in regulatory and academic pharmaceutical sciences. In my discipline of systems pharmacology, I expect that this will act as a catalyst for new and better collaborations and cross-fertilisation in research, training and education. This should ultimately have a positive impact on the development of novel personalized medicines for patients.”
The dialogue between EMA and academia has already improved in time, but this is the perfect moment to structure this interaction and bring it to the next level, commented Dr. Rosa Giuliani, EU Policy Committee, European Society for Medical Oncology (ESMO).
“The framework of collaboration is a timely initiative, which is expected to fulfil specific tasks,” she said. “This is the platform needed to 1) promote regulatory awareness, 2) support academic research and 3) boost communication between the two parties. Now it is time to work!”
To view the full release, click herePhilip Ward is the European Editor for Applied Clinical Trials
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.